WO2007050607A3 - Novel use of il-1beta compounds - Google Patents

Novel use of il-1beta compounds Download PDF

Info

Publication number
WO2007050607A3
WO2007050607A3 PCT/US2006/041479 US2006041479W WO2007050607A3 WO 2007050607 A3 WO2007050607 A3 WO 2007050607A3 US 2006041479 W US2006041479 W US 2006041479W WO 2007050607 A3 WO2007050607 A3 WO 2007050607A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
receptor
rheumatoid arthritis
antibodies
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/041479
Other languages
French (fr)
Other versions
WO2007050607A2 (en
Inventor
Phil Lowe
Hermann Gram
Thomas Jung
Timothy Wright
Trevor Mundel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007050607(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to ES06826560T priority Critical patent/ES2389110T3/en
Priority to DK06826560.2T priority patent/DK1940465T3/en
Priority to NO20211027A priority patent/NO20211027A1/en
Priority to CA2626214A priority patent/CA2626214C/en
Priority to EP06826560A priority patent/EP1940465B1/en
Priority to KR1020177008682A priority patent/KR20170038131A/en
Priority to AU2006306280A priority patent/AU2006306280B2/en
Priority to SI200631412T priority patent/SI1940465T1/en
Priority to NZ567222A priority patent/NZ567222A/en
Priority to EP23155348.8A priority patent/EP4218815A3/en
Priority to KR1020147035512A priority patent/KR101749388B1/en
Priority to EP17199544.2A priority patent/EP3332807B1/en
Priority to JP2008537878A priority patent/JP2009513645A/en
Priority to HK09100171.2A priority patent/HK1121041B/en
Priority to NO20200810A priority patent/NO345888B1/en
Priority to US12/090,490 priority patent/US8105587B2/en
Priority to PL06826560T priority patent/PL1940465T3/en
Priority to BRPI0617830A priority patent/BRPI0617830B8/en
Priority to KR1020087009981A priority patent/KR101518064B1/en
Priority to RU2008120625/15A priority patent/RU2468817C2/en
Priority to CN200680039395XA priority patent/CN101291693B/en
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Publication of WO2007050607A2 publication Critical patent/WO2007050607A2/en
Publication of WO2007050607A3 publication Critical patent/WO2007050607A3/en
Priority to IL190545A priority patent/IL190545A/en
Priority to TNP2008000189A priority patent/TNSN08189A1/en
Anticipated expiration legal-status Critical
Priority to NO20082344A priority patent/NO345140B1/en
Priority to US13/283,165 priority patent/US8409576B2/en
Priority to US13/777,609 priority patent/US20130171167A1/en
Priority to PH12013501287A priority patent/PH12013501287B1/en
Priority to LU92326C priority patent/LU92326I2/en
Priority to LTPA2013026C priority patent/LTC1940465I2/en
Priority to CY2013046C priority patent/CY2013046I2/en
Priority to US14/810,556 priority patent/US9649377B2/en
Priority to IL245387A priority patent/IL245387B/en
Priority to US15/484,459 priority patent/US20170218063A1/en
Priority to US15/918,136 priority patent/US20180201674A1/en
Priority to IL258983A priority patent/IL258983B/en
Priority to US16/906,118 priority patent/US20210147533A1/en
Priority to PH12020500559A priority patent/PH12020500559A1/en
Priority to IL277406A priority patent/IL277406A/en
Priority to US18/175,849 priority patent/US20240083997A1/en
Priority to US19/217,696 priority patent/US20260125463A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)

Abstract

This application relates to a use of IL-lβ ;-ligand/IL-l receptor disrupting compounds (herein referred to as 'IL-lbeta Compounds') ; such as small molecular compounds disrupting IL-lβ; ligand - IL-I receptor interaction, IL-lβ; antibodies or IL-I receptor antibodies, e.g. IL-lβ; binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-lβ; binding compounds or IL-I receptor binding compounds, and/or RNA compounds decreasing either IL-lβ; ligands or IL-I receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans .
PCT/US2006/041479 2005-10-26 2006-10-24 Novel use of il-1beta compounds Ceased WO2007050607A2 (en)

Priority Applications (40)

Application Number Priority Date Filing Date Title
AU2006306280A AU2006306280B2 (en) 2005-10-26 2006-10-24 Novel use of IL-1beta compounds
KR1020147035512A KR101749388B1 (en) 2005-10-26 2006-10-24 Novel use of il-1beta compounds
NO20211027A NO20211027A1 (en) 2005-10-26 2006-10-24 Use of IL-1beta compounds
CA2626214A CA2626214C (en) 2005-10-26 2006-10-24 Novel use of il-1beta compounds
EP06826560A EP1940465B1 (en) 2005-10-26 2006-10-24 Novel use of anti il-1beta antibodies
KR1020177008682A KR20170038131A (en) 2005-10-26 2006-10-24 Novel use of il-1beta compounds
EP17199544.2A EP3332807B1 (en) 2005-10-26 2006-10-24 Use of anti il-1beta antibodies
SI200631412T SI1940465T1 (en) 2005-10-26 2006-10-24 Novel use of anti il-1beta antibodies
NZ567222A NZ567222A (en) 2005-10-26 2006-10-24 Novel use of IL-1beta compounds
EP23155348.8A EP4218815A3 (en) 2005-10-26 2006-10-24 Use of anti il-1beta antibodies
PL06826560T PL1940465T3 (en) 2005-10-26 2006-10-24 Novel use of anti il-1beta antibodies
ES06826560T ES2389110T3 (en) 2005-10-26 2006-10-24 New use of anti-IL-1beta antibodies
DK06826560.2T DK1940465T3 (en) 2005-10-26 2006-10-24 New use of anti-IL-1beta antibodies
HK09100171.2A HK1121041B (en) 2005-10-26 2006-10-24 Novel use of anti il-1beta antibodies
NO20200810A NO345888B1 (en) 2005-10-26 2006-10-24 A medicament for use in the treatment of familial Mediterranean fever comprising a human IL-1-beta binding antibody and a pharmaceutical composition comprising the antibody for use in the treatment of familial Mediterranean fever.
US12/090,490 US8105587B2 (en) 2005-10-26 2006-10-24 Methods of treating arthritis using IL-1β binding molecules
JP2008537878A JP2009513645A (en) 2005-10-26 2006-10-24 Novel use of IL-1β compounds
BRPI0617830A BRPI0617830B8 (en) 2005-10-26 2006-10-24 use of an il-1beta binding antibody and pharmaceutical compositions comprising the same
KR1020087009981A KR101518064B1 (en) 2005-10-26 2006-10-24 -1 novel use of il-1beta compounds
RU2008120625/15A RU2468817C2 (en) 2005-10-26 2006-10-24 NEW APPLICATION OF IL-1β COMPOUNDS
CN200680039395XA CN101291693B (en) 2005-10-26 2006-10-24 New uses of IL-1β compounds
IL190545A IL190545A (en) 2005-10-26 2008-03-31 Use of Human IL-1 Beta-Conjugated Antibodies to Prepare Drugs for the Treatment of Juvenile Idiopathic Arthritis
TNP2008000189A TNSN08189A1 (en) 2005-10-26 2008-04-25 Novel use of il-1beta compounds
NO20082344A NO345140B1 (en) 2005-10-26 2008-05-23 Use of human IL-1beta binding antibodies and pharmaceutical compositions containing them, for the manufacture of a medicament for the treatment of juvenile rheumatoid arthritis
US13/283,165 US8409576B2 (en) 2005-10-26 2011-10-27 Use of IL-1beta compounds
US13/777,609 US20130171167A1 (en) 2005-10-26 2013-02-26 Methods of Using IL-1beta Compounds
PH12013501287A PH12013501287B1 (en) 2005-10-26 2013-06-18 Novel use of il-1beta compounds
LU92326C LU92326I2 (en) 2005-10-26 2013-12-05 Canakinumab and its pharmaceutically acceptable derivatives (ILARIS)
LTPA2013026C LTC1940465I2 (en) 2005-10-26 2013-12-06 New use of anti-IL-1 beta antibodies
CY2013046C CY2013046I2 (en) 2005-10-26 2013-12-13 NOVEL USE OF IL-1BHTA ANTIBODIES
US14/810,556 US9649377B2 (en) 2005-10-26 2015-07-28 Methods of using IL-1β compounds to treat familial mediterranean fever (FMF)
IL245387A IL245387B (en) 2005-10-26 2016-05-02 A drug for use in the treatment of familial Mediterranean fever containing an antibody that binds to human IL-1 beta
US15/484,459 US20170218063A1 (en) 2005-10-26 2017-04-11 Methods of Using IL-1beta Compounds
US15/918,136 US20180201674A1 (en) 2005-10-26 2018-03-12 Methods of Using IL-1beta Compounds
IL258983A IL258983B (en) 2005-10-26 2018-04-26 A new use for il–1 beta compounds
US16/906,118 US20210147533A1 (en) 2005-10-26 2020-06-19 Methods of Using IL-1beta Compounds
PH12020500559A PH12020500559A1 (en) 2005-10-26 2020-06-23 Novel use of il-1beta compounds
IL277406A IL277406A (en) 2005-10-26 2020-09-16 Novel use of il-1beta compounds
US18/175,849 US20240083997A1 (en) 2005-10-26 2023-02-28 Methods of Using IL-1beta Compounds
US19/217,696 US20260125463A1 (en) 2005-10-26 2025-05-23 Methods of Using IL-1beta Compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73043505P 2005-10-26 2005-10-26
US60/730,435 2005-10-26
US74212505P 2005-12-02 2005-12-02
US60/742,125 2005-12-02

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/090,490 A-371-Of-International US8105587B2 (en) 2005-10-26 2006-10-24 Methods of treating arthritis using IL-1β binding molecules
US13/283,165 Continuation US8409576B2 (en) 2005-10-26 2011-10-27 Use of IL-1beta compounds

Publications (2)

Publication Number Publication Date
WO2007050607A2 WO2007050607A2 (en) 2007-05-03
WO2007050607A3 true WO2007050607A3 (en) 2007-06-28

Family

ID=37806690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/041479 Ceased WO2007050607A2 (en) 2005-10-26 2006-10-24 Novel use of il-1beta compounds

Country Status (28)

Country Link
US (9) US8105587B2 (en)
EP (5) EP2848258B1 (en)
JP (4) JP2009513645A (en)
KR (3) KR101518064B1 (en)
CN (2) CN101291693B (en)
AU (1) AU2006306280B2 (en)
BR (1) BRPI0617830B8 (en)
CA (3) CA2898369C (en)
CY (4) CY1113378T1 (en)
DK (2) DK1940465T3 (en)
ES (3) ES2944067T3 (en)
HU (2) HUE036973T2 (en)
IL (4) IL190545A (en)
JO (2) JO2826B1 (en)
LT (3) LT2848258T (en)
LU (2) LU92326I2 (en)
MA (1) MA29919B1 (en)
NO (2) NO345888B1 (en)
NZ (1) NZ567222A (en)
PH (2) PH12013501287B1 (en)
PL (2) PL1940465T3 (en)
PT (2) PT1940465E (en)
RU (2) RU2468817C2 (en)
SI (2) SI1940465T1 (en)
TN (1) TNSN08189A1 (en)
TR (1) TR201802449T4 (en)
TW (3) TWI388335B (en)
WO (1) WO2007050607A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2848258B1 (en) * 2005-10-26 2017-12-13 Novartis AG Treatment of familial Mediterranean Fever with anti IL-1beta antibodies
AU2012203931B2 (en) * 2007-05-29 2014-04-24 Novartis Ag New indications for anti-IL-I-beta therapy
EP3406263A1 (en) * 2007-05-29 2018-11-28 Novartis AG New indications for anti-il-1beta therapy
CA2727171A1 (en) * 2008-06-06 2009-12-10 Xoma Technology Ltd. Methods for the treatment of rheumatoid arthritis
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
TW201124427A (en) * 2009-10-15 2011-07-16 Abbott Lab IL-1 binding proteins
AU2011252883B2 (en) * 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
WO2012121775A2 (en) * 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
EP3426775A1 (en) 2016-03-10 2019-01-16 Novartis AG Chemically modified messenger rna's
US11162943B2 (en) 2017-05-31 2021-11-02 Prometheus Biosciences Inc. Methods for assessing mucosal healing in Crohn's disease patients
UY37758A (en) 2017-06-12 2019-01-31 Novartis Ag METHOD OF MANUFACTURING OF BIESPECTIFIC ANTIBODIES, BISPECTIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES
US20190048072A1 (en) 2017-06-22 2019-02-14 Novartis Ag USE OF IL-1beta BINDING ANTIBODIES
CN112584857A (en) * 2018-05-09 2021-03-30 诺华股份有限公司 Use of Kanagilu monoclonal antibody
WO2020128636A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
JP2022514087A (en) 2018-12-21 2022-02-09 ノバルティス アーゲー Use of IL-1β binding antibody
TWI793503B (en) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 ANTI-IL-1β ANTIBODIES
EP4464329A4 (en) * 2022-01-10 2025-06-11 GI Innovation, Inc. Pharmaceutical composition for the prevention or treatment of degenerative brain diseases with glucagon-like peptide-1 and interleukin-1 receptor antagonist

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
WO2001053353A2 (en) * 2000-01-21 2001-07-26 Novartis Ag Recombinant antibodies to human interkleukin-1 beta
WO2002016436A2 (en) * 2000-08-22 2002-02-28 Novartis Ag ANTIBODIES TO HUMAN IL-1$g(b)
WO2003010282A2 (en) * 2001-07-26 2003-02-06 Eli Lilly And Company Interleukin-1 beta antibodies
WO2004067568A2 (en) * 2003-01-24 2004-08-12 Applied Molecular Evolution, Inc Human il-1 beta antagonists

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2284161T3 (en) 1990-01-12 2007-11-01 Amgen Fremont Inc. GENERATION OF XENOGENIC ANTIBODIES.
US5350683A (en) * 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0690673A4 (en) 1993-12-14 1996-05-29 Univ Pittsburgh SYSTEMIC GENE TREATMENT OF CONNECTIVE TISSUE CONDITIONS
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
JP2003500005A (en) 1999-02-10 2003-01-07 インターリューキン ジェネティックス インコーポレイテッド Treatment and diagnosis based on mutations in the IL-1β gene
DK1210320T3 (en) * 1999-07-16 2005-01-31 Leo Pharma As Aminobenzophenones as inhibitors of IL-1beta and TNF-alpha
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
EP2241328A1 (en) * 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
SG159378A1 (en) 2000-11-07 2010-03-30 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
EP1450837A4 (en) * 2001-08-07 2006-01-04 Immunex Corp Interleukin-1 receptors in the treatment of diseases
ES2385823T3 (en) 2001-12-01 2012-08-01 Iskra Wind Turbines Ltd. Synchronous AC generator that incorporates a braking mechanism
KR200268109Y1 (en) 2001-12-06 2002-03-15 김정훈 Flat noncommutator vibration motor
JP2005519917A (en) 2002-02-01 2005-07-07 オメロス コーポレイション Compositions and methods for systemic inhibition of cartilage degradation
BR0307544A (en) 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Phosphorus-containing compounds, components and composition as well as their use by treatment methods
CA2474360A1 (en) * 2002-02-11 2003-08-21 Arkion Life Sciences Llc Purified cytokine inhibitory factor
PE20040079A1 (en) 2002-04-03 2004-04-19 Novartis Ag INDOLYLMALEIMIDE DERIVATIVES
WO2004052359A1 (en) 2002-12-09 2004-06-24 The Board Of Regents Of The University Of Texas System Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
AU2005249503B2 (en) * 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
AU2004290413A1 (en) 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring IL-18
US20080207613A1 (en) 2004-01-12 2008-08-28 Cytopia Research Pty Ltd Selective Kinase Inhibitors
AU2005216298B2 (en) * 2004-02-26 2010-09-02 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
AU2005249570B2 (en) * 2004-06-04 2011-06-16 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat autoinflammatory disease
JP2009501128A (en) 2005-01-20 2009-01-15 ユニバーシティー オブ ロチェスター Compositions and methods for the study and treatment of inflammatory diseases and disorders
EP2371967B1 (en) 2005-03-18 2015-06-03 DSM IP Assets B.V. Production of carotenoids in oleaginous yeast and fungi
ES2569917T3 (en) 2005-06-21 2016-05-13 Xoma (Us) Llc Antibodies and fragments thereof that bind to IL-1beta
EP2848258B1 (en) * 2005-10-26 2017-12-13 Novartis AG Treatment of familial Mediterranean Fever with anti IL-1beta antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
WO2001053353A2 (en) * 2000-01-21 2001-07-26 Novartis Ag Recombinant antibodies to human interkleukin-1 beta
WO2002016436A2 (en) * 2000-08-22 2002-02-28 Novartis Ag ANTIBODIES TO HUMAN IL-1$g(b)
WO2003010282A2 (en) * 2001-07-26 2003-02-06 Eli Lilly And Company Interleukin-1 beta antibodies
WO2004067568A2 (en) * 2003-01-24 2004-08-12 Applied Molecular Evolution, Inc Human il-1 beta antagonists

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOISSIER M G ET AL: "Protection of collagen-induced arthritis with active immunization against peptides of interleukin-1 (IL-1) beta inducing self anti-IL-1 beta antibodies", ANNALS OF THE RHEUMATIC DISEASES, vol. 64, no. Suppl. 3, July 2005 (2005-07-01), & ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY; VIENNA, AUSTRIA; JUNE 08 11, 2005, pages 170, XP008077941, ISSN: 0003-4967 *
DINARELLO CHARLES A: "Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS,, NL, vol. 4, no. 4, August 2004 (2004-08-01), pages 378 - 385, XP002357660, ISSN: 1471-4892 *
FLEISHMANN R M: "Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2002 SEP-OCT, vol. 20, no. 5 Suppl 27, September 2002 (2002-09-01), pages S35 - S41, XP002429835, ISSN: 0392-856X *
FORSTER ADRIAN ET AL: "Neue Studien an der Rheumaklinik: Patienten gesucht", RHEUMANACHRICHTEN, vol. 34, April 2004 (2004-04-01), Zürich, pages 20, XP002429833, Retrieved from the Internet <URL:http://www.rheumaportal.ch/downloads/rheumanachrichten/nachrichten/34/Rheumanachrichten_34.pdf> [retrieved on 20070416] *
GEIGER T ET AL: "NEUTRALIZATION OF INTERLEUKIN-1 BETA ACTIVITY IN VIVO WITH A MONOCLONAL ANTIBODY ALLEVIATES COLLAGEN-INDUCED ARTHRITIS IN DBA/1 MICE AND PREVENTS THE ASSOCIATED ACUTE-PHASE RESPONSE", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, PACINI, PISA, IT, vol. 11, no. 5, September 1993 (1993-09-01), pages 515 - 522, XP009081237, ISSN: 0392-856X *
GILARDI ET AL.: "Novartis highlights pharmaceutical research strategy, intensifying focus on molecular pathways shared by various diseases", NOVARTIS, 3 May 2005 (2005-05-03), internet, pages 1 - 4, XP002429834, Retrieved from the Internet <URL:http://cws.huginonline.com/N/134323/PR/200505/992453_5.html> [retrieved on 20070418] *
HAWKINS ET AL: "INTERLEUKIN-1-RECEPTOR ANTAGONIST IN THE MUCKLE-WELLS SYNDROME", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 348, no. 25, 19 June 2003 (2003-06-19), pages 2583 - 2584, XP009054112, ISSN: 1533-4406 *

Also Published As

Publication number Publication date
EP3332807B1 (en) 2023-02-22
WO2007050607A2 (en) 2007-05-03
IL190545A (en) 2016-09-29
HUE036973T2 (en) 2018-08-28
TW201617097A (en) 2016-05-16
PT1940465E (en) 2012-10-03
US20210147533A1 (en) 2021-05-20
IL277406A (en) 2020-11-30
MA29919B1 (en) 2008-11-03
LTC1940465I2 (en) 2017-12-11
JP2013166757A (en) 2013-08-29
DK1940465T3 (en) 2012-10-22
HK1252316A1 (en) 2019-05-24
JOP20140120B1 (en) 2021-08-17
SI2848258T1 (en) 2018-03-30
KR101749388B1 (en) 2017-06-20
DK2848258T3 (en) 2018-03-19
JP2017206552A (en) 2017-11-24
TWI626056B (en) 2018-06-11
HUS1800025I1 (en) 2018-07-30
EP4218815A3 (en) 2024-03-27
RU2008120625A (en) 2010-01-20
ES2944067T3 (en) 2023-06-19
US20150322148A1 (en) 2015-11-12
LTPA2018506I1 (en) 2018-06-25
TW201302220A (en) 2013-01-16
US20170218063A1 (en) 2017-08-03
CY2018018I1 (en) 2018-12-12
KR20150013834A (en) 2015-02-05
TR201802449T4 (en) 2018-03-21
IL245387B (en) 2019-09-26
CY2018018I2 (en) 2018-12-12
EP2848258A1 (en) 2015-03-18
LTC2848258I2 (en) 2019-08-12
CY1120018T1 (en) 2018-12-12
CA2898369A1 (en) 2007-05-03
LU92326I2 (en) 2014-02-05
US20260125463A1 (en) 2026-05-07
US9649377B2 (en) 2017-05-16
NZ567222A (en) 2011-07-29
EP3332807A2 (en) 2018-06-13
IL190545A0 (en) 2008-11-03
CN101291693B (en) 2012-10-03
BRPI0617830A2 (en) 2011-08-09
PT2848258T (en) 2018-03-20
JP2009513645A (en) 2009-04-02
EP1940465A2 (en) 2008-07-09
CA2963828A1 (en) 2007-05-03
HK1204767A1 (en) 2015-12-04
US8409576B2 (en) 2013-04-02
US20130171167A1 (en) 2013-07-04
ES2662420T3 (en) 2018-04-06
RU2012133522A (en) 2014-02-20
US20080286266A1 (en) 2008-11-20
NO345140B1 (en) 2020-10-12
BRPI0617830B1 (en) 2020-10-20
ES2389110T3 (en) 2012-10-23
CA2626214C (en) 2016-06-21
AU2006306280A1 (en) 2007-05-03
TWI537003B (en) 2016-06-11
EP2332577A1 (en) 2011-06-15
PH12013501287A1 (en) 2016-02-01
TWI388335B (en) 2013-03-11
CY2013046I1 (en) 2015-11-04
PH12020500559A1 (en) 2021-06-14
US20180201674A1 (en) 2018-07-19
LU92326I9 (en) 2019-01-16
PH12013501287B1 (en) 2016-02-01
AU2006306280B2 (en) 2010-06-17
IL258983B (en) 2020-10-29
KR101518064B1 (en) 2015-05-06
HK1121041A1 (en) 2009-04-17
KR20170038131A (en) 2017-04-05
US20240083997A1 (en) 2024-03-14
RU2571563C2 (en) 2015-12-20
EP4218815A2 (en) 2023-08-02
IL245387A0 (en) 2016-06-30
LT2848258T (en) 2018-02-26
EP2848258B1 (en) 2017-12-13
CY1113378T1 (en) 2015-11-04
EP3332807A3 (en) 2018-06-20
JP6286403B2 (en) 2018-02-28
NO345888B1 (en) 2021-09-27
RU2468817C2 (en) 2012-12-10
EP1940465B1 (en) 2012-08-01
SI1940465T1 (en) 2012-10-30
PL1940465T3 (en) 2013-01-31
TNSN08189A1 (en) 2009-10-30
IL258983A (en) 2018-06-28
NO20200810A1 (en) 2008-07-22
JP2016020377A (en) 2016-02-04
JP6061747B2 (en) 2017-01-18
KR20080059598A (en) 2008-06-30
BRPI0617830B8 (en) 2021-05-25
CA2898369C (en) 2017-06-20
CN101291693A (en) 2008-10-22
NO20082344L (en) 2008-07-22
CY2013046I2 (en) 2015-11-04
US8105587B2 (en) 2012-01-31
PL2848258T3 (en) 2018-06-29
JO2826B1 (en) 2014-09-15
CN102861332A (en) 2013-01-09
CA2626214A1 (en) 2007-05-03
TW200803898A (en) 2008-01-16
LUC00078I2 (en) 2018-08-14
US20120039910A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
PH12020500559A1 (en) Novel use of il-1beta compounds
EP4177268A3 (en) New indications for anti-il-1beta therapy
WO2005011592A3 (en) Substituted indazole-o-glucosides
WO2005012243A3 (en) Substituted indole-o-glucosides
WO2006003407A3 (en) Chimeric and humanised monoclonal antibodies against inteleukin- 13
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
TW200736274A (en) Immunoglobulins
WO2006133164A3 (en) Anti-trkb monoclonal antibodies and uses thereof
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
WO2009135861A3 (en) Humanized antibodies against human interferon-alpha
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2005111083A3 (en) Antibodies specific for glycoprotein vi and methods of producing these antibodies
WO2007120651A3 (en) Uses and compositions for treatment of juvenile rheumatoid arthritis
WO2001064889A3 (en) Tnf-alpha variants for the treatment of tnf-alpha related disorders
WO2004035732A3 (en) Human polypeptides encoded by polynucleotides and methods of their use
WO2004075838A3 (en) Method and compositions for the treatment of meconium aspiration syndrome
WO2003074073A3 (en) Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof
WO2007068750A3 (en) Immunoglobulins directed against nogo
WO2009015063A8 (en) Methods and compositions for treating fibrosis related disorders using il-17 antagonists
WO2004098536A3 (en) Anti-viral activity of cathelicidin peptides
WO2004075863A3 (en) Cxcr3 antagonists
WO2003039468A3 (en) Antimnemonic therapy for hypermemory syndromes
WO2006122123A3 (en) Methods of alleviating disorders and their associated pain
WO2006012504A3 (en) Compounds and methods for treatment of thrombosis
WO2006124699A3 (en) Blockade of pin1 prevents cytokine production by activated immune cells

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680039395.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006826560

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 190545

Country of ref document: IL

Ref document number: 12008500776

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 567222

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006306280

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008040616

Country of ref document: EG

ENP Entry into the national phase

Ref document number: 2626214

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12090490

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/005340

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2008537878

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: DZP2008000324

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2008120625

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0617830

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080425

WWE Wipo information: entry into national phase

Ref document number: 1020147035512

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: IDP00201502347

Country of ref document: ID

WWE Wipo information: entry into national phase

Ref document number: 245387

Country of ref document: IL